絞り込み

16426

広告

856件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer.

Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.

Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer.

Improvement of erosive pustular dermatosis of the scalp following discontinuation of chemotherapy with afatinib.

[A case report of afatinib-induced interstitial lung disease].

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.

[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります